Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 823-830

  Park, Seok Woo ^a   Kim, Hyo Sun ^a   Hah, Jeong Whun ^a   Jeong, Woo Jin ^a   Kim, Kwang Hyun ^a,b   Sung, Myung Whun ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

celecoxib; head and neck cancer; mitogen activated protein kinase; tumor killing

Indexed keywords

CELECOXIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEAD AND NECK NEOPLASMS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; SULFONAMIDES; UP-REGULATION;

EID: 77956419985     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833dada8     Document Type: Article

References (30)

1. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006; 15:471-477.
2. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005; 4:1358-1363.
3. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11:8213-8221.
4. Tsutsumi R, Ito H, Hiramitsu T, Nishitani K, Akiyoshi M, Kitaori T, et al. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol Int 2008; 28:727-736.
5. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 2005; 11:1999-2007.
6. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2- independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Faseb J 2005; 19:1353-1355.
7. Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, et al. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007; 13:4750-4758.
8. Backhus LM, Petasis NA, Uddin J, Schonthal AH, Bart RD, Lin Y, et al. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130:1406-1412.
9. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-COX-2)-dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67:1469-1478.
10. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 2003; 8:649-654.
11. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006; 42:422-426.
12. Cho SD, Ahn NS, Jung JW, Yang SR, Park JS, Lee YS, et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev 2006; 15:57-63.
13. Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 2010; 49:13-24.
14. Yang Z, Mu J, Chen J, Ge Q, Liao Y, Lu Q, Huang Z. Apoptosis of U937 cell line promoted by matrine through MAPK signal transduction pathway. Zhongguo Zhong Yao Za Zhi 2009; 34:1553-1556.
15. Talbert DR, Allred CD, Zaytseva YY, Kilgore MW. Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 2008; 108:23-33.
16. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004; 10:125-129.
17. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002; 25:511-518.
18. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003; 74:143-153.
19. Elder DJ, Halton DE, Playle LC, Paraskeva C. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99:323-327.
20. Park SW, Lee SG, Song SH, Heo DS, Park BJ, Lee DW, et al. The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int J Cancer 2003; 107:729-738.
21. Baek SJ,Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301:1126-1131.
22. Honjo S, Osaki M, Ardyanto TD, Hiramatsu T, Maeta N, Ito H. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 2005; 24:141-147.
23. Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 2005; 65:982-990.
24. Shao J, Evers BM, Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 2004; 279:14287-14293.
25. Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63:5218-5223.
26. Sheng H, Shao J,Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-18081.
27. Gao J, Niwa K, Takemura M, Sun W, Onogi K, Wu Y, et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 2005; 26:737-744.
28. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005; 111:1685-1689.
29. Sperandio da Silva GM, Lima LM, Fraga CA, SantAnna CM, Barreiro EJ. The molecular basis for celecoxib inhibition of p38alpha MAP kinase. Bioorg Med Chem Lett 2005; 15:3506-3509.
30. Gallicchio M, Rosa AC, Dianzani C, Brucato L, Benetti E, Collino M, et al. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). Br J Pharmacol 2008; 153:870-878. (Pubitemid 351328933)